Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS axis

Molecules and Cells

Volumn 38-38, Issue 7-7, 2015, Pages 638-642

  Zhang, Xian ^a   Guo, Qinggong ^a   Chen, Jingtao ^a   Chen, Zhaohui ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Cisplatin; KRAS; MicroRNA 217; Osteosarcoma; Quercetin

Indexed keywords

CISPLATIN; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 217; QUERCETIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MIRN217 MICRORNA, HUMAN; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; METASTASIS; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OSTEOSARCOMA; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE; HUMANS; MICRORNAS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS P21(RAS); QUERCETIN;

EID: 84950280761     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.0037     Document Type: Article

References (21)

1. Berndt, K., Campanile, C., Muff, R., Strehler, E., Born, W., and Fuchs, B. (2013). Evaluation of quercetin as a potential drug in osteosarcoma treatment. Anticancer Res. 33, 1297-1306.
2. Bielack, S.S., Carrle, D., Hardes, J., Schuck, A., and Paulussen, M. (2008). Bone tumors in adolescents and young adults. Curr. Treat Options Oncol. 9, 67-80.
3. Chou, A.J., Gupta, R., Bell, M.D., Riewe, K.O., Meyers, P.A., and Gorlick, R. (2013). Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr. Blood Cancer 60, 580-586.
4. Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., and Kroemer, G. (2012). Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883.
5. Guo, J.H., Feng, Z.J., Huang, Z., Wang, H.Y., and Lu, W.J. (2014). MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol. Cells 37, 664-671.
6. Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., Gunn, A., Nakagawa, Y., Shimano, H., Todorov, I., et al. (2009). TGFbeta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 11, 881-263.
7. Kim, J.Y., Kim, E.H., Park, S.S., Lim, J.H., Kwon, T.K., and Choi, K.S. (2008). Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 upregulation and proteasome-mediated c-FLIPS down-regulation. J. Cell Biochem. 105, 1386-1398.
8. Li, N., Sun, C., Zhou, B., Xing, H., Ma, D., Chen, G., and Weng, D. (2014). Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One 9, e100314.
9. Liang, W., Li, X., Li, C., Liao, L., Gao, B., Gan, H., Yang, Z., and Chen, X. (2011). Quercetin-mediated apoptosis via activation of the mitochondrial-dependent pathway in MG-63 osteosarcoma cells. Mol. Med. Rep. 4, 1017-1023.
10. Martinez-Velez, N., Xipell, E., Jauregui, P., Zalacain, M., Marrodan, L., Zandueta, C., Vera, B., Urquiza, L., Sierrasesumaga, L., Julian, M.S., et al. (2014). The oncolytic adenovirus Delta24-RGD in combination with cisplatin exerts a potent antiosteosarcoma activity. J. Bone Miner Res. 29, 2287-2296.
11. Orsolic, N., and Car, N. (2014). Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo. Tumour. Biol. 35, 6445-6454.
12. Scambia, G., Ranelletti, F.O., Benedetti Panici, P., Bonanno, G., De Vincenzo, R., Piantelli, M., and Mancuso, S. (1990). Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anticancer Drugs 1, 45-48.
13. Shen, D.W., Pouliot, L.M., Hall, M.D., and Gottesman, M.M. (2012). Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64, 706-721.
14. SS, B. (2012). A review of quercetin: Antioxidant and anticancer properties. World J. Pharm. Pharm. Sci. 1, 146-160.
15. Suh, D.K., Lee, E.J., Kim, H.C., and Kim, J.H. (2010). Induction of G(1)/S phase arrest and apoptosis by quercetin in human osteosarcoma cells. Arch. Pharm. Res. 33, 781-785.
16. Wang, P., Vadgama, J.V., Said, J.W., Magyar, C.E., Doan, N., Heber, D., and Henning, S.M. (2014). Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J. Nutr. Biochem. 25, 73-80.
17. Wu, J., Liao, Q., He, H., Zhong, D., and Yin, K. (2014). TWIST interacts with beta-catenin signaling on osteosarcoma cell survival against cisplatin. Mol. Carcinog. 53, 440-446.
18. Xie, X.B., Yin, J.Q., Jia, Q., Wang, J., Zou, C.Y., Brewer, K.J., Colombo, C., Wang, Y.F., Huang, G., and Shen, J.N. (2011). Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of Akt. Oncol. Rep. 26, 687-693.
19. Yi, L., Zongyuan, Y., Cheng, G., Lingyun, Z., Guilian, Y., and Wei, G. (2014). Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 105, 520-527.
20. Zhao, W.G., Yu, S.N., Lu, Z.H., Ma, Y.H., Gu, Y.M., and Chen, J. (2010). The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31, 1726-1733.
21. Zhao, G.Y., Cai, C.K., Yang, T.T., Qiu, X.C., Liao, B., Li, W., Ji, Z.W., Zhao, J., Zhao, H.E., Guo, M.J., et al. (2013). MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 8, e53906.